Pentostatin

Drug Profile

Pentostatin

Alternative Names: 2'-Deoxycoformycin; CI 825; Coforin; DCF; Deoxycoformycin; Nipent; Nipentin; NSC 218321; Oncopent; PD 81565; YK 176

Latest Information Update: 14 Sep 2015

Price : $50

At a glance

  • Originator National Cancer Institute (USA); Pfizer
  • Developer Hospira; National Cancer Institute (USA); Pfizer
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Adenosine deaminase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hairy cell leukaemia
  • No development reported Cutaneous T cell lymphoma
  • Discontinued Graft-versus-host disease; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Sep 2015 Hospira has been acquired by Pfizer
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top